Vatalanib (dihydrochloride)

Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.

Product Specifications

CAS Number

[212141-51-0]

Product Name Alternative

PTK787 (dihydrochloride) ; ZK-222584 (dihydrochloride) ; CGP-797870 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; VEGFR

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vatalanib-dihydrochloride.html

Purity

99.68

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 50 mg/mL (ultrasonic)

Smiles

ClC1=CC=C(C=C1)NC2=NN=C(C3=C2C=CC=C3)CC4=CC=NC=C4.[H]Cl.[H]Cl

Molecular Formula

C20H17Cl3N4

Molecular Weight

419.73

Precautions

H302, H315, H319, H335

References & Citations

[1]Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60 (8|[2]Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18 (2), 589-596.|[3]Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35 (3) :1297-308.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Isoform

VEGFR2/KDR/Flk-1

Citation 01

Bioact Mater. 2022 Jan 2:15:131-144.|Br J Pharmacol. 2019 Sep;176 (17) :3143-3160. |Evid Based Complement Alternat Med. 2021 Apr 26:2021:5543259.|JCI Insight. 2024 May 22;9 (10) :e166402.|Kitasato University. Kitasato University. 2017.|Oncol Rep. 2016 Mar;35 (3) :1297-308.|Oxid Med Cell Longev. 2022 Jul 18:2022:2232365.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Ulm University. 2023 Mar 21.|Drug Metab Pharmacokinet. 2017 Jun;32 (3) :179-188. |Int J Mol Sci. 2024 Nov 15;25 (22) :12277.|J Microbiol Biotechnol. 2015 Aug;25 (8) :1227-33. |J Pharm Anal. 2024 Jan;14 (1) :100-114.|Mutat Res. 2025 Sep 24:831:111916.|Patent. US20170349880A1.